Company SAMSUNG PHARM. Co., LTD.

A001360

KR7001360007

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sector Generic Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1,718 ^KRW	+1.72%		+5.08%	-21.01%

2023	NEXTURNBIOSCIENCE Co., Ltd. announced that it has received KRW 7 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd.	CI
2023	NEXTURNBIOSCIENCE Co., Ltd. announced that it expects to receive KRW 9 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd.	CI

SAMSUNG PHARM. Co., LTD., formerly SAMSUNG PHARMACEUTICAL.CO.,Ltd., is a Korea-based company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. The Pharmaceutical and Quasi-drug Sale Business segment manufactures and sells prescription medicines, general pharmaceuticals and quasi-medicines. This segment's products include anticancer immunotherapy agents, antipyretic analgestic and anti-inflammatory agents, hypotensive agents, antiarteriosclerotic agents, anti-spastics, enzyme agents, ostepoposis agents, antibiotics, medicines for digestive system, medicines for liver disorder, medicines for circulation system and vitamin supplements, among others. The Health Food Manufacturing and Sale segment manufactures and sells nutrition and invigoration products.

Number of employees: 240

KRW in Million	2022	Weight	2023	Weight	Delta
Pharmaceuticals and Quasi-drugs 100.0 %	51,832	100.0 %	51,955	100.0 %	+0.24%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 100.0 %	51,832	100.0 %	51,955	100.0 %	+0.24%

Managers	Title	Age	Since
Ki-Ho Kim CEO	Chief Executive Officer	57	-
Sang-Jae Kim CEO	Chief Executive Officer	57	-
Chang-Bum Woo AUD	Comptroller/Controller/Auditor	55	-

Members of the board	Title	Age	Since
Woo-Jin Kim BRD	Director/Board Member	70	-
Sang-Jae Kim CEO	Chief Executive Officer	57	-
Gi-Woong Kim BRD	Director/Board Member	57	20-03-24
Ki-Ho Kim CEO	Chief Executive Officer	57	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	94,162,079	84,257,460 ( 89.48 %)	46,245 ( 0.0491 %)	89.48 %

Name	Equities	%	Valuation
GEMVAX&KAEL CO.,LTD. 10.46 %	9,852,179	10.46 %	13 M ₩
SAMSUNG PHARM. CO., LTD. 0.0492 %	46,310	0.0492 %	62 194 ₩
Kyung-Pyo Jung 0.004723 %	4,447	0.004723 %	5 972 ₩
DFA Australia Ltd. 0.004628 %	4,358	0.004628 %	5 853 ₩
Bong-kwon Park 0.001856 %	1,748	0.001856 %	2 348 ₩
Korea Investment Management Co., Ltd. 0.000254 %	239	0.000254 %	321 ₩

Name	Equities	%	Valuation
GEMVAX&KAEL CO.,LTD. 5.01%	2,005,424	5.01%	17,547,921 $
FLASK CO., LTD. 1.09%	1,438,738	1.09%	843,201 $
SAMSUNG PHARM. CO., LTD. 0.05%	46,310	0.05%	62,194 $

SAMSUNG PHARMACEUTICAL Co., Ltd.

35 Jeyakgongdan 2-gil Hyangnam-eup

18622, Hwaseong

http://www.sspharm.co.kr

address SAMSUNG PHARM. Co., LTD.(A001360)

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Generic Pharmaceuticals

	1st Jan change	Capi.
SAMSUNG PHARM. CO., LTD.	-21.01%	117M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.27%	43.18B
OTSUKA HOLDINGS CO., LTD.	+24.05%	23.23B
SANDOZ GROUP AG	+15.11%	14.6B
CIPLA LIMITED	+12.33%	13.54B
ZYDUS LIFESCIENCES LIMITED	+38.36%	11.5B
ONO PHARMACEUTICAL CO., LTD.	-7.63%	6.79B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+10.21%	5.31B

Generic Pharmaceuticals